Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same author

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

The oncologist·2026

Same author

Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.

JAMA oncology·2026

Same author

Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol.

PloS one·2026

Same author

NSCLC in Vulnerable and Special Populations: Toward Personalized Care.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Same journal

[Prolonged fever].

La Revue du praticien·2026

Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026

Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026

Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026

Same journal

[Patient education in heart failure].

La Revue du praticien·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Feb 1, 2026

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

[Thymic tumors].

Nicolas Girard^1,2, Claire Merveilleux Du Vignaux^1,2, Thierry Molina^1,3

¹Centre expert national pour la prise en charge des thymomes et carcinomes thymiques, RYTHMIC, Réseau tumeurs thymiques et cancer.

La Revue Du Praticien

|December 5, 2018

Summary

This summary is machine-generated.

Thymic epithelial tumors, rare and aggressive, include thymomas and thymic carcinomas. Complete surgical resection is key for survival, with chemotherapy and radiotherapy for unresectable cases.

Keywords:

Maladies rares Tumeurs thymiques

More Related Videos

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Published on: April 3, 2011

Preparation and Applications of Organotypic Thymic Slice Cultures

Preparation and Applications of Organotypic Thymic Slice Cultures

Published on: August 6, 2016

Related Experiment Videos

Last Updated: Feb 1, 2026

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Derivation of Thymic Lymphoma T-cell Lines from Atm-/- and p53-/- Mice

Published on: April 3, 2011

Preparation and Applications of Organotypic Thymic Slice Cultures

Preparation and Applications of Organotypic Thymic Slice Cultures

Published on: August 6, 2016

Area of Science:

Oncology
Pathology

Background:

Thymic epithelial tumors are rare, aggressive malignancies with variable prognoses.
Histopathological classification separates thymomas and thymic carcinomas.
Autoimmune conditions, like myasthenia gravis, affect approximately one-third of patients.

Purpose of the Study:

To outline the diagnostic and therapeutic strategies for thymic malignancies.
To highlight the importance of surgical resectability in patient survival.
To introduce the RYTHMIC network for managing thymic malignancies.

Main Methods:

Histopathological classification of thymic epithelial tumors.
Assessment of tumor resectability as a primary therapeutic step.
Multimodal treatment approaches including chemotherapy, surgery, and radiotherapy for unresectable tumors.

Main Results:

Complete tumor resection is the most significant prognostic factor for survival.
Unresectable thymic tumors are managed with induction chemotherapy followed by surgery or radiotherapy.
The RYTHMIC network was established in 2012 to centralize expert management.

Conclusions:

Effective management of thymic tumors requires accurate histopathological diagnosis and assessment of resectability.
A multidisciplinary approach involving chemotherapy, surgery, and radiotherapy is crucial for unresectable cases.
Specialized networks like RYTHMIC enhance the care of patients with rare thymic malignancies.